Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 11/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | POLR1A | O95602 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16625315 | 0.93 | MCHR1 (0.45) | MCHR1HRH3USP30 | |
| SCHEMBL16625305 | 0.93 | MCHR1 (0.43) | MCHR1HRH3USP30CCR5 | |
| SCHEMBL16625306 | 0.93 | MCHR1 (0.42) | MCHR1HRH3USP30CCR5 | |
| SCHEMBL28511552 | 0.85 | P4HB (0.42) | — | |
| SCHEMBL16625313 | 0.83 | HRH3 (0.47) | MCHR1HRH3USP30CCR5 | |
| SCHEMBL16625310 | 0.82 | MCHR1 (0.39) | MCHR1 | |
| SCHEMBL16625309 | 0.81 | USP30 (0.66) | USP30 | |
| SCHEMBL16625311 | 0.81 | LIMK2 (0.41) | MCHR1 | |
| SCHEMBL28499994 | 0.80 | HSD11B1 (0.43) | USP30 | |
| SCHEMBL28499992 | 0.80 | HSD11B1 (0.43) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | MCHR1 4692/4885HRH3 3405/4885USP30 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.